Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008
Phototherapy is among our most powerful weapons for fighting against chronic inflammatory skin diseases. Since the middle of the past century, numerous controlled studies of broadband UV-B, narrowband UV-B, and psoralen plus UV-A have demonstrated that phototherapy is highly effective in treating cutaneous diseases, such as psoriasis and atopic dermatitis. In 1981, the development of a new lamp that emits radiation predominantly between 340 and 400 nm was described, introducing the era of UV-A1 phototherapy.1 Three different dosage regimens of UV-A1 are distinguished: high-, medium-, and low-dose UV-A1, emitting 90 to 130, 30 to 89, and less than 30 J/cm2, respectively. In contrast to UV-B, which penetrates into the papillary dermis only, longer wavelengths in the UV-A region can reach the subcutis as well. In 1992, UV-A1 was first introduced as a highly potent treatment option for acute atopic dermatitis.2 Three years later, a letter reported that UV-A1 was capable of reducing skin sclerosis in patients with localized scleroderma (LS).3 Since then, a variety of case reports and uncontrolled open studies have been published on UV-A1 phototherapy for sclerotic skin diseases.
Kreuter A, Gambichler T. UV-A1 Phototherapy for Sclerotic Skin Diseases: Implications for Optimizing Patient Selection and Management. Arch Dermatol. 2008;144(7):912–916. doi:10.1001/archderm.144.7.912
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: